Laser light therapy for retinal changes from macular degeneration
Part of Eyes & vision clinical trials.
This trial tests whether a special laser (photobiomodulation) can help slow or improve vision loss from reticular pseudodrusen, a specific type of retinal damage seen in age-related macular degeneration. The laser delivers safe light energy to stimulate healing in the eye.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 50 or older
- Diagnosed reticular pseudodrusen (a specific eye condition) in at least one eye—confirmed by eye exam
- Vision between 20/20 and 20/400 (mild to moderate vision loss is okay; severe loss disqualifies)
- Willing to attend all study visits and follow instructions
- No advanced retinal damage (geographic atrophy or abnormal blood vessel growth)
- No prior AMD treatments except vitamin supplements; no previous eye surgery in the past 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if repeated low-level red-light therapy can help people with dry age-related macular degeneration (AMD), a condition that causes gradual vision loss. The therapy uses red light to potentially slow or improve vision problems.
This trial studies a mild (“subthreshold”) laser treatment for reticular pseudodrusen (RPD) caused by age-related macular degeneration (AMD). If you qualify, the goal is to see whether the laser helps preserve or improve vision by targeting these specific eye changes.
This trial tests a new light-based treatment for intermediate age-related macular degeneration (AMD), a common eye condition that can lead to vision loss. The goal is to see if it is safe and helps slow down the disease.
This study tests a new laser treatment (MacuTherm) for intermediate age-related macular degeneration (iAMD), an eye condition that affects central vision. The study aims to see if this treatment can slow or prevent progression to more advanced stages of the disease.
This trial tests whether a special light treatment (photobiomodulation) can help people with dry age-related macular degeneration (AMD). It is designed for those with early to moderate dry AMD who still have fairly good vision.
This trial studies whether a light-based treatment (photobiomodulation) can help people with dry age-related macular degeneration in one eye. Because one eye is treated while the other eye has a different type of AMD in the study design, eligibility depends on which type of AMD you have in each eye.
Hear when a new AMD - Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.